Generic Drugs Stocks on Investors' Radar -- Zoetis, Sophiris Bio, Rigel Pharma, and Neurocrine Biosciences

Sep 20, 2016, 07:35 ET from Chelmsford Park SA

NEW YORK, September 20, 2016 /PRNewswire/ --

Despite stiff pricing competition, the Generic Drugs industry remains an attractive place for investors given its resilience to market downturns and continued growth in emerging economies. This morning, redirects its attention to the following stocks: Zoetis Inc. (NYSE: ZTS), Sophiris Bio Inc. (NASDAQ: SPHS), Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), and Neurocrine Biosciences Inc. (NASDAQ: NBIX) to see how they fared over the last few trading sessions. Learn more about these stocks by downloading their comprehensive and free reports at:


On Monday, shares in Florham Park, New Jersey headquartered Zoetis Inc. recorded a trading volume of 2.43 million shares. The stock ended the day at $50.32, which was a slight drop of 0.38%. The Company's shares have gained 7.49% over the previous three months and 5.68% on an YTD basis. The stock is trading above its 200-day moving average by 8.23%. Furthermore, shares of Zoetis, which engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the US and internationally, have a Relative Strength Index (RSI) of 44.05.

On August 21st, 2016, Zoetis announced that Glenn David, Senior Vice President of Finance Operations, has been named Executive Vice President and Chief Financial Officer and will assume responsibility for the oversight of the company's financial management, planning and global operations, effective immediately. David will report directly to CEO Juan Ramón Alaix and become part of the Zoetis Executive Team. ZTS complete research report is just a click away and free at:

Sophiris Bio  

La Jolla, California-based Sophiris Bio Inc.'s stock finished yesterday's session 1.02% lower at $2.90, with a total trading volume of 1.51 million shares. The Company's shares have surged 59.34% in the previous three months and 62.92% on an YTD basis. The stock is trading above its 200-day moving average by 31.07%. Furthermore, shares of Sophiris Bio, which focuses on the development of products for the treatment of urological diseases, have an RSI of 40.91.

On August 26th, 2016, Sophiris Bio announced that it has closed its previously announced underwritten public offering. With the proceeds from the offering, the company plans to conduct a second Phase 2 clinical trial of topsalysin for the treatment of localized prostate cancer.

On September 15th, 2016, research firm ROTH Capital initiated a 'Buy' rating on the Company's stock, issuing a target price of $8 per share. The complimentary report on SPHS can be downloaded at:

Rigel Pharma  

At the closing bell on Monday, shares in South San Francisco, California-based Rigel Pharmaceuticals Inc. saw a decline of 2.29%, ending the day at $3.42. The stock recorded a trading volume of 681,014 shares. The Company's shares have advanced 15.93% in the last one month, 39.02% in the previous three months, and 12.87% since the start of this year. The stock is trading 22.62% and 29.88% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Rigel Pharmaceuticals, which engages in the discovery and development of novel and targeted drug candidates in the therapeutic areas of immunology, oncology, and immuno-oncology, have an RSI of 59.18.

On August 31st, 2016, research firm H.C. Wainwright reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $6 a share to $7 a share.

On September 15th, 2016, Rigel Pharmaceuticals announced plans to build a commercial organization to support the potential launch of fostamatinib, its oral SYK inhibitor, for the treatment of chronic immune thrombocytopenia. The company recently reported that fostamatinib met the primary endpoint in the first of two identical Phase 3 studies in chronic ITP. Results of the second Phase 3 clinical study are expected in late October or early November.  Sign up for your complimentary research report on RIGL at:

Neurocrine Biosciences  

San Diego, California headquartered Neurocrine Biosciences Inc.'s stock ended the day 0.11% higher at $54.06. A total volume of 1.31 million shares traded, which was above their three months average volume of 940,420 shares. The Company's shares have gained 12.60% in the last month and 21.98% over the previous three months. The stock is trading 9.42% above its 50-day moving average and 18.34% above its 200-day moving average. Additionally, shares of Neurocrine Biosciences, which discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the US, have an RSI of 65.62.

On September 1st, 2016, Neurocrine Biosciences announced that the FDA has conditionally accepted the proprietary name "INGREZZA™" for the company's once-daily vesicular monoamine transporter 2 (VMAT2) inhibitor valbenazine. The Company has recently announced the submission of a New Drug Application with the FDA for valbenazine in tardive dyskinesia and is also exploring its utility in Tourette syndrome.  Get free access to your research report on NBIX at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA